Publications and communications of Kaoutar HAFRAOUI

Lombardo, G., HAFRAOUI, K., Beguin, Y., & VERTENOEIL, G. (February 2024). Comment j’explore … une polyglobulie. Revue Médicale de Liège, 79 (2), 110 - 115.

WITHOFS, N., Beguin, Y., COUSIN, F., Tancredi, T., SIMONI, P., Alvarez-Miezentseva, V., DE PRIJCK, B., HAFRAOUI, K., Bonnet, C., Baron, F., Hustinx, R., & Caers, J. (2019). Dual-tracer PET/CT scan after injection of combined [ 18 F]NaF and [ 18 F]FDG outperforms MRI in the detection of myeloma lesions. Hematological Oncology, 37, 193-201. doi:10.1002/hon.2600

Huart, J., Visée, C., Colassin, A., Marechal, P., HAFRAOUI, K., & Davin, L. (July 2018). Syndrome coronarien aigu lié à une maladie de Vaquez. Revue Médicale de Liège, 73 (7-8), 397 - 401.

SID, S., Baron, F., WILLEMS, E., Caers, J., Bonnet, C., DE PRIJCK, B., LEJEUNE, M., HAFRAOUI, K., Servais, S., JASPERS, A., & Beguin, Y. (November 2016). Hematologic recovery after autologus stem cell transplantation in multiple myeloma: a single center experience of 225 patients [Paper presentation]. 16ème Congrès commun de la SFGM-TC & 8ème de la SFBCT, Liège, Belgium.

WITHOFS, N., COUSIN, F., TANCREDI, T., SIMONI, P., DE PRIJCK, B., HAFRAOUI, K., BONNET, C., HUSTINX, R., BEGUIN, Y., & CAERS, J. (14 June 2016). Comparison of combined whole-body 18F-NAF and 18F-FDG PET/CT versus MRI for the detection of myeloma lesions [Paper presentation]. SNMMI 2016 Annual Meeting.

Grégoire, C., GUIOT, J., Vertenoeil, G., WILLEMS, E., HAFRAOUI, K., CORHAY, J.-L., LOUIS, R., & BEGUIN, Y. (February 2016). Yellow nail syndrome after allogeneic haematopoietic stem cell transplantation in two patients with multiple myeloma. Acta Clinica Belgica, 71, 428-430. doi:10.1080/17843286.2015.1122872

JASPERS, A., Baron, F., SERVAIS, S., LEJEUNE, M., WILLEMS, E., SEIDEL, L., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (September 2015). Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival. American Journal of Hematology, 90 (9), 197-199. doi:10.1002/ajh.24100

JASPERS, A., Baron, F., Maertens, J., DE PRIJCK, B., Schots, R., Bonnet, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & Beguin, Y. (July 2015). Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation [letter to the editor]. American Journal of Hematology, 90 (7), 133-4. doi:10.1002/ajh.24013

JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948.

CAERS, J., HAFRAOUI, K., KEUTGENS, A., CABERG, J.-H., LAMBERT, F., TASSIN, F., & BEGUIN, Y. (02 February 2014). Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide. European Journal of Haematology, 92 (2), 179-180. doi:10.1111/ejh.12233

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (2014). Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation. Belgian Journal of Hematology, 14.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2014). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomized trial. Blood, 124, 33-41. doi:10.1182/blood-2014-01-546333

BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552

HAFRAOUI, K., CAERS, J., TASSIN, F., & Beguin, Y. (2013). Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide [Poster presentation]. BHS 28th General Annual Meeting, Gent, Belgium.

HAFRAOUI, K., DE PRIJCK, B., & Beguin, Y. (2013). Leucémie myélomonocytaire chronique : diagnostic et thérapeutique. Revue Médicale Suisse, 9, 1512-1517.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2013). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial. Belgian Journal of Hematology, 16.

Bonnet, C., CAERS, J., DE PRIJCK, B., HAFRAOUI, K., & Beguin, Y. (2011). Lymphome du manteau : prise en charge 2011. Revue Médicale Suisse, 7, 1644-1649.

Baron, F., Lechanteur, C., Willems, E., Bruck, F., Baudoux, E., Seidel, L., Vanbellinghen, J.-F., Hafraoui, K., LEJEUNE, M., Gothot, A., Fillet, G., & Beguin, Y. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 16 (6), 838-47. doi:10.1016/j.bbmt.2010.01.011

Baron, F., WILLEMS, E., LECHANTEUR, C., BAUDOUX, E., Frere, P., Vanbellinghen, J., Bruck, F., Gothot, A., HAFRAOUI, K., Fillet, G., & Beguin, Y. (2009). Co-transplantation of mesenchymal stem cells might mitigate acute GvHD without abrogating graftversus- tumour alloreactivity after allogeneic transplantation with non-myeloablative conditioning [Paper presentation]. 35th EBMT Annual Meeting.

Beguin, Y., Maertens, J., DE PRIJCK, B., Schots, R., Frère, P., Bonnet, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., LEJEUNE, M., SERVAIS, S., THeunissen, K., Fillet, G., & Baron, F. (2009). A prospective randomized multicenter trial of darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation [Poster presentation]. 24th General Meeting of the Belgian Hematological Society, Oostende, Belgium.

Hafraoui, K., Beguin, Y., & Baron, F. (2009). Cancers secondaires après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 64 (10), 496-499.

Hafraoui, K., Moutschen, M., Smet, J., Mascart, F., Schaaf-Lafontaine, N., & Fillet, G. (2009). Selective defect of anti-pneumococcal IgG in a patient with persistent polyclonal B cell lymphocytosis. European Journal of Internal Medicine, 20 (3), 62-5. doi:10.1016/j.ejim.2008.08.005

Willems, E.* , Baron, F.* , Baudoux, E., Wanten, N., Seidel, L., Vanbellinghen, J.-F., Herens, C., Gothot, A., Frere, P., Bonnet, C., Hafraoui, K., Vanstraelen, G., Fillet, G., & Beguin, Y. (2009). Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial. Leukemia, 23 (3), 608-10. doi:10.1038/leu.2008.248
* These authors have contributed equally to this work.

Frere, P., Baron, F., Bonnet, C., Hafraoui, K., Pereira-Martins, M., Willems, E., Fillet, G., & Beguin, Y. (2006). Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplantation, 37 (4), 411-8. doi:10.1038/sj.bmt.1705255

Vanstraelen, G., Baron, F., Willems, E., Bonnet, C., Hafraoui, K., Frere, P., Fillet, G., & Beguin, Y. (2006). Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response. Experimental Hematology, 34 (7), 841-50. doi:10.1016/j.exphem.2006.04.012

WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2006). Nonmyeloablative stem cell transplantation with CD8-depleted or unmalipulated peripheral blood stem cells: a prospective randomized trial [Paper presentation]. 21st General Meeting of the Belgian Hematological Society.

Vanstraelen, G., Baron, F., Frere, P., Hafraoui, K., Fillet, G., & Beguin, Y. (2005). Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica, 90 (9), 1269-70.

WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2005). Nonmyeloablative stem cell transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a prospective randomized trial. Blood, 106 (1075).

Hafraoui, K., Humblet-Baron, S., Baron, F., Beguin, Y., & Fillet, G. (2003). Comment je traite ... la leucemie myeloide chronique (LMC). Revue Médicale de Liège, 58 (1), 7-12.